A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 1, 2010

Primary Completion Date

April 12, 2012

Study Completion Date

January 16, 2014

Conditions
LeukemiaSolid Tumours
Interventions
DRUG

SB939

"Dose Levels for Part A~-1 - 20mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~1. (starting dose) 25mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~2. \- 35mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~3. \- 45mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~4+ - Previous level + 10mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing"

Trial Locations (8)

T3B 6A8

Alberta Children's Hospital, Calgary

T6G 2B7

Stollery Children's Hospital, Edmonton

V6H 3V4

Children's and Women's Health Centre of BC Branch, Vancouver

R3E 0V9

CancerCare Manitoba, Winnipeg

B3K 6R8

Izaak Walton Killam (IWK) Health Centre, Halifax

K1H 8L1

Children's Hospital of Eastern Ontario, Ottawa

M5G 1X8

Hospital for Sick Children, Toronto

H3T 1C5

CHU Sainte-Justine, Montreal

Sponsors
All Listed Sponsors
collaborator

S*BIO

INDUSTRY

lead

NCIC Clinical Trials Group

NETWORK